JP2022551458A5 - - Google Patents
Info
- Publication number
- JP2022551458A5 JP2022551458A5 JP2022521144A JP2022521144A JP2022551458A5 JP 2022551458 A5 JP2022551458 A5 JP 2022551458A5 JP 2022521144 A JP2022521144 A JP 2022521144A JP 2022521144 A JP2022521144 A JP 2022521144A JP 2022551458 A5 JP2022551458 A5 JP 2022551458A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- composition according
- hantavirus
- rodent
- infection
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| LULU101430 | 2019-10-08 | ||
| LU101430 | 2019-10-08 | ||
| EP19203601.0 | 2019-10-16 | ||
| EP19203601 | 2019-10-16 | ||
| PCT/EP2020/078104 WO2021069486A1 (en) | 2019-10-08 | 2020-10-07 | Mek inhibitors for the treatment of hantavirus infections |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022551458A JP2022551458A (ja) | 2022-12-09 |
| JP2022551458A5 true JP2022551458A5 (enExample) | 2023-10-17 |
| JP7802365B2 JP7802365B2 (ja) | 2026-01-20 |
Family
ID=73037924
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022521144A Active JP7802365B2 (ja) | 2019-10-08 | 2020-10-07 | ハンタウイルス感染症の処置のためのｍｅｋ阻害剤 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20220378730A1 (enExample) |
| EP (1) | EP4041212B1 (enExample) |
| JP (1) | JP7802365B2 (enExample) |
| KR (1) | KR20220079573A (enExample) |
| CN (1) | CN114786659B (enExample) |
| AU (1) | AU2020362953A1 (enExample) |
| BR (1) | BR112022005896A2 (enExample) |
| ES (1) | ES3045883T3 (enExample) |
| MX (1) | MX2022004259A (enExample) |
| WO (1) | WO2021069486A1 (enExample) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3973960B1 (en) | 2017-10-17 | 2025-09-03 | Atriva Therapeutics GmbH | Novel mek-inhibitor for the treatment of viral and bacterial infections |
| LU101183B1 (en) * | 2019-04-16 | 2020-10-16 | Atriva Therapeutics Gmbh | Novel mek-inhibitor for the treatment of viral and bacterial infections |
| AU2021206684B2 (en) | 2020-01-10 | 2024-01-18 | Immuneering Corporation | MEK inhibitors and therapeutic uses thereof |
| TW202508595A (zh) | 2023-05-04 | 2025-03-01 | 美商銳新醫藥公司 | 用於ｒａｓ相關疾病或病症之組合療法 |
| CN116585294B (zh) * | 2023-06-05 | 2025-06-17 | 中国人民解放军空军军医大学 | 大黄素在制备抗汉滩病毒药物中的应用 |
| US20250049810A1 (en) | 2023-08-07 | 2025-02-13 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| AU2024360465A1 (en) | 2023-10-12 | 2026-04-09 | Revolution Medicines, Inc. | Macrocyclic ras inhibitors |
| WO2025171296A1 (en) | 2024-02-09 | 2025-08-14 | Revolution Medicines, Inc. | Ras inhibitors |
| TW202547461A (zh) | 2024-05-17 | 2025-12-16 | 美商銳新醫藥公司 | Ｒａｓ抑制劑 |
| WO2025255438A1 (en) | 2024-06-07 | 2025-12-11 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| WO2025265060A1 (en) | 2024-06-21 | 2025-12-26 | Revolution Medicines, Inc. | Therapeutic compositions and methods for managing treatment-related effects |
| WO2026006747A1 (en) | 2024-06-28 | 2026-01-02 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026015801A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015790A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015796A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015825A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Use of ras inhibitor for treating pancreatic cancer |
| WO2026050446A1 (en) | 2024-08-29 | 2026-03-05 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026072904A2 (en) | 2024-09-26 | 2026-04-02 | Revolution Medicines, Inc. | Compositions and methods for treating lung cancer |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE10017480A1 (de) | 2000-04-07 | 2001-10-11 | Transmit Technologietransfer | Verwendung von Substanzen, die als MEK Inhibitor wirken, zur Herstellung eines Arneimittels gegen DNA- und RNA-Viren |
| CN101461805B (zh) * | 2009-01-16 | 2010-07-28 | 武汉大学 | 一种抗汉坦病毒药物阿比朵尔的用途 |
| WO2014056894A1 (en) | 2012-10-08 | 2014-04-17 | Westfaelische Wilhelms-Universitaet Muenster | Mek inhibitors in the treatment of virus diseases |
| CN113398271A (zh) | 2014-05-16 | 2021-09-17 | 归属疗法有限公司 | 抗流感病毒和金黄色葡萄球菌合并感染的新型抗感染策略 |
| DE102014111892A1 (de) * | 2014-08-20 | 2016-02-25 | Eberhard Karls Universität Tübingen Medizinische Fakultät | Prophylaxe und Behandlung einer Infektion mit dem Hantavirus |
| EP3973960B1 (en) | 2017-10-17 | 2025-09-03 | Atriva Therapeutics GmbH | Novel mek-inhibitor for the treatment of viral and bacterial infections |
-
2020
- 2020-10-07 JP JP2022521144A patent/JP7802365B2/ja active Active
- 2020-10-07 BR BR112022005896A patent/BR112022005896A2/pt unknown
- 2020-10-07 MX MX2022004259A patent/MX2022004259A/es unknown
- 2020-10-07 ES ES20799621T patent/ES3045883T3/es active Active
- 2020-10-07 EP EP20799621.6A patent/EP4041212B1/en active Active
- 2020-10-07 US US17/767,186 patent/US20220378730A1/en active Pending
- 2020-10-07 CN CN202080084724.2A patent/CN114786659B/zh active Active
- 2020-10-07 KR KR1020227013461A patent/KR20220079573A/ko active Pending
- 2020-10-07 AU AU2020362953A patent/AU2020362953A1/en active Pending
- 2020-10-07 WO PCT/EP2020/078104 patent/WO2021069486A1/en not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022551458A5 (enExample) | ||
| CN114786659B (zh) | 用于治疗汉坦病毒感染的mek抑制剂 | |
| US20220125767A1 (en) | Thiazolide compounds for treating viral infections | |
| JP2020537659A (ja) | ウイルス感染および細菌感染の処置のための新規ｍｅｋ阻害剤 | |
| Rebeaud et al. | SARS-CoV-2 and the Use of Chloroquine as an Antiviral Treatment | |
| CN115916162A (zh) | 用于冠状病毒治疗的吡非尼酮 | |
| KR20210120891A (ko) | 유행성 rna 바이러스 감염질환의 예방 또는 치료용 약제학적 조성물 | |
| JP2025124703A (ja) | ウイルス感染および細菌感染の治療のための新規ｍｅｋ阻害剤 | |
| WO2022020967A1 (en) | Use of wnt/beta-catenin pathway inhibitors to block replication of sars-cov-2 and other pathogenic viruses | |
| ES2937145T3 (es) | Azelastina como tratamiento antiviral | |
| Hayden | Experimental human influenza: observations from studies of influenza antivirals | |
| EP4527410A1 (en) | Composition for inhibiting coronaviruses or enteroviruses | |
| CA3152450C (en) | Mek inhibitors for the treatment of hantavirus infections | |
| IT201600074507A1 (it) | Uso di xibornolo come agente attivo nel trattamento di infezioni virali | |
| HK40081976B (zh) | 用於预防或治疗流行性rna病毒传染病的药物组合物 | |
| HK40090283B (en) | Local administration of nicotinic acetylcholine receptor agonists for the inhibition of coronavirus infections | |
| JP2011530585A5 (enExample) | ||
| Castro | The role of reactive oxygen species as mediators of respiratory syncytial virus induced pulmonary inflammation |